Looking back: does this HAE drug work in everyday life?

NCT ID NCT07263685

Not yet recruiting Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

Summary

This study aims to understand how well the preventive drug Takhzyro works for people with hereditary angioedema (HAE) in real-world settings in Saudi Arabia. Researchers will review the medical records of about 50 patients who have taken the drug for at least six months to see if it reduced their swelling attacks and improved their quality of life. No new treatment is given; the study only looks at past patient data.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • King Faisal Specialist Hospital and Research Centre

    Riyadh, 12713, Saudi Arabia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.